Skip to content

Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease

Conservative Versus Surgical Treatment of Umbilical Pilonidal Sinus Disease: A Prospective, Randomised, and Multicenter Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01662765
Enrollment
84
Registered
2012-08-10
Start date
2003-11-30
Completion date
2012-05-31
Last updated
2017-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pilonidal Sinus, Sinus; Dermal, Pilonidal, Umbilical Granuloma

Keywords

Umbilical pilonidal sinus, Treatment, Surgery, Conservative, Investigational treatment, After care

Brief summary

The aim of the study was to compare the results of conservative and surgical treatment, to create an algorithm for the management of the disease, and gain more information about the etiology, pathogenesis, and course of the disease. The investigators hypothesise that surgical treatment of UPS will be better than conservative management in terms of recurrence rate, healing time, patient comfort and satisfaction, and cost effectiveness.

Detailed description

Because of its rarity, umbilical pilonidal sinus (UPS) is still poorly understood in terms of diagnosis, etiology, and the best treatment options. UPS is thought caused by hair penetrating the skin, leading to a foreign-body reaction and development of a sinus lined with granulation tissue. Most of the patients complain of pain, discharge or bleeding from the umbilicus when symptoms develop. It can be diagnosed with a careful examination, in which hairs can be seen deep in the umbilicus and usually protrude from a small sinus. Regarding the optimal treatment of the disease, a complete consensus has not yet been achieved. Some publications are recommended conservative treatment, while surgical treatment is recommended in others. A more meaningful comparison of the two modalities is that of a randomized controlled trial. We, therefore, present our data of prospective randomized controlled clinical trial comparing conservative versus surgical treatment of UPS. This was a multicenter, prospective balanced randomization, double blind, active-controlled, parallel-group, superiority study conducted in Turkey, under the direction of a principal investigator (MK). Eligible patients with UPS were randomized for either conservative treatment (CT) or surgical treatment (ST), and then the results of both groups were compared.

Interventions

PROCEDURESurgery

modified umbilectomy

this treatment will include conservative procedures under local anesthesia for patient comfort.

Sponsors

Zeugma Saglik Hizmetleri San. Tic. Ltd. Sti.
CollaboratorINDUSTRY
Medical Park Gaziantep Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* all patients willing to participate to the study with the diagnosis of umbilical pilonidal sinus

Exclusion criteria

* no informed consent * serious coagulation abnormalities * known allergy to local anesthetics * pregnancy, or women who refused contraception at the time of treatment * other concomitant umbilical pathologies such as umbilical hernia, granuloma, dermoid cyst * the patients who diagnosed with urachal and omphalomesenteric anomalies through radiological investigation * patients who underwent umbilical operation

Design outcomes

Primary

MeasureTime frameDescription
Cure Rate2 year after initial treatmentPrimary outcome was the cure rate. Absence of recurrence within two year after the first treatment was considered as a cure. Recurrence was defined as the appearance of a new, active discharging sinus or granulation tissue with/without a bit of hairs in the deep of the umbilicus within two years after therapy.

Secondary

MeasureTime frameDescription
Healing Timetwo yearthe time form initial treatment to healing the wound and/or sinus and/or granulation tissue and no any sign of drainage with no longer need for dressing and wound care in either treatment arms.
Visual Analogue Scale for Patient Satisfaction (VAS-PS)30 daysWell-being and satisfaction scales comprised linear metric scales known as visual analogue scales, with grades from 0 (worst imaginable health state and extremely dissatisfied with the treatment) to 100 (best imaginable health state and extremely satisfied with the treatment).

Other

MeasureTime frameDescription
Coststwo yearfrom initial treatment to the complete healing, all kind of cost will be calculated.

Countries

Turkey (Türkiye)

Participant flow

Participants by arm

ArmCount
Conservative
Conservative treatment described as follow: Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus. postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry.
42
Surgery
Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium. Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination.
42
Total84

Baseline characteristics

CharacteristicConservativeSurgeryTotal
Age, Continuous21.80 years19.86 years20.83 years
Gender
Female
3 Participants2 Participants5 Participants
Gender
Male
39 Participants40 Participants79 Participants
Region of Enrollment
Turkey
42 participants42 participants84 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 420 / 42
serious
Total, serious adverse events
0 / 420 / 42

Outcome results

Primary

Cure Rate

Primary outcome was the cure rate. Absence of recurrence within two year after the first treatment was considered as a cure. Recurrence was defined as the appearance of a new, active discharging sinus or granulation tissue with/without a bit of hairs in the deep of the umbilicus within two years after therapy.

Time frame: 2 year after initial treatment

Population: Of the 84 patients 41 patients in the CT group. and 40 patients in ST group were analyzed

ArmMeasureValue (NUMBER)
ConservativeCure Rate28 participants
SurgeryCure Rate40 participants
Secondary

Healing Time

the time form initial treatment to healing the wound and/or sinus and/or granulation tissue and no any sign of drainage with no longer need for dressing and wound care in either treatment arms.

Time frame: two year

ArmMeasureValue (MEAN)Dispersion
ConservativeHealing Time12.81 daysStandard Deviation 2.96
SurgeryHealing Time17.06 daysStandard Deviation 5.1
Secondary

Visual Analogue Scale for Patient Satisfaction (VAS-PS)

Well-being and satisfaction scales comprised linear metric scales known as visual analogue scales, with grades from 0 (worst imaginable health state and extremely dissatisfied with the treatment) to 100 (best imaginable health state and extremely satisfied with the treatment).

Time frame: 30 days

ArmMeasureValue (MEAN)Dispersion
ConservativeVisual Analogue Scale for Patient Satisfaction (VAS-PS)66 units on a scaleStandard Deviation 8
SurgeryVisual Analogue Scale for Patient Satisfaction (VAS-PS)71 units on a scaleStandard Deviation 6
Other Pre-specified

Costs

from initial treatment to the complete healing, all kind of cost will be calculated.

Time frame: two year

ArmMeasureValue (MEAN)Dispersion
ConservativeCosts609 USD dollarsStandard Deviation 224
SurgeryCosts479 USD dollarsStandard Deviation 75

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026